AOD-9604 Anesthesia and Perioperative Interaction: What You Need to Know

What Is AOD-9604 and Why Does Its Mechanism Matter Before Surgery?

AOD-9604 is a 16-amino-acid C-terminal fragment of human growth hormone, spanning residues 176 to 191. It was originally developed by Metabolic Pharmaceuticals (Melbourne, Australia) as an anti-obesity agent. Unlike full-length growth hormone, it does not activate the main GH receptor in a way that raises insulin-like growth factor-1 (IGF-1) or causes insulin resistance, which is a key distinction for perioperative metabolic management.

The Beta-3 Adrenergic Pathway

The peptide's primary pharmacological action is partial agonism at beta-3 adrenergic receptors in adipose tissue. Beta-3 adrenergic receptors control lipolysis in white adipose tissue and thermogenesis in brown adipose tissue. This pathway is distinct from the beta-1 and beta-2 receptors that most cardiovascular anesthetic considerations focus on, which means AOD-9604 is unlikely to directly alter heart rate or bronchomotor tone in the way that traditional beta-agonists do [1].

A 2001 Phase II study published in data submitted to the TGA (Australia's Therapeutic Goods Administration) demonstrated that AOD-9604 at doses up to 1 mg/kg produced no statistically significant changes in fasting glucose, fasting insulin, or IGF-1 compared with placebo over 12 weeks [2]. That metabolic neutrality is clinically relevant: anesthesiologists managing patients on full-length GH secretagogues must account for potential insulin resistance and fluid retention, but the same blanket concern does not automatically apply to AOD-9604.

Why the Absence of FDA Approval Matters

The FDA has not approved AOD-9604 for any indication. In 2014, the FDA reclassified it as a drug rather than a dietary supplement ingredient, prohibiting its inclusion in commercial supplements [3]. This classification means there is no official prescribing label, no manufacturer-provided drug interaction table, and no perioperative guidance from a regulatory package insert. Clinicians and patients are therefore working from first-principles pharmacology and the limited clinical trial record.

Published Clinical Safety Data: What the Trials Actually Show

Phase IIb METAOD Trial

The most rigorous human safety data comes from the METAOD Phase IIb trial conducted in Australia, which enrolled 299 overweight adults and tested AOD-9604 at doses of 1 mg/day orally for 24 weeks [4]. The trial found no clinically significant abnormalities in liver function tests, renal panels, complete blood counts, or ECG parameters. No episodes of hypoglycemia were recorded in the treatment arms. This broad metabolic and cardiovascular safety profile is reassuring for perioperative risk stratification, although the trial was not designed to detect rare anesthesia-specific events.

Subcutaneous Formulation Data

Most current clinical use involves subcutaneous injection of 200 to 300 mcg once daily, a route and dose different from the oral formulation tested in METAOD. The subcutaneous pharmacokinetics show a peak plasma concentration (Tmax) of approximately 15 minutes post-injection and a half-life of roughly 30 minutes [5]. By 4 hours post-injection, plasma levels are effectively undetectable. This rapid clearance is important for perioperative timing: even same-day administration would result in negligible plasma levels by the time most surgical procedures begin, assuming a standard morning injection is skipped.

The HealthRX perioperative framework for injectable research peptides applies here. Peptides with half-lives under 2 hours and no documented coagulation effects can generally be paused 7 days before elective surgery to allow washout of any downstream receptor-level adaptations, not just the parent compound. Peptides with half-lives above 6 hours or known platelet effects require extended pauses of 14 or more days. AOD-9604 falls into the first category under this framework.

Anesthesia-Specific Interaction Risks: A Systematic Review of the Evidence

No published randomized controlled trial, case series, or pharmacokinetic interaction study has specifically examined AOD-9604 combined with general anesthetics, regional anesthetics, or sedative agents. That absence of data is itself a data point, and it cuts in both directions.

Theoretical Interactions With Volatile Anesthetics

Volatile anesthetic agents such as sevoflurane and desflurane produce dose-dependent decreases in systemic vascular resistance and myocardial contractility. These agents are also known to modulate adrenergic signaling pathways. Because AOD-9604 acts on beta-3 adrenergic receptors in adipose tissue rather than cardiac or vascular smooth muscle, direct hemodynamic combination is not mechanistically expected. Still, no human pharmacodynamic study has co-administered these agents, so the possibility cannot be excluded with certainty [6].

Interaction With Propofol and Midazolam

Propofol is primarily metabolized via glucuronidation in the liver and extrahepatic tissues. Midazolam is a CYP3A4 substrate. AOD-9604, as a short peptide, is metabolized by ubiquitous serum and tissue peptidases rather than hepatic cytochrome P450 enzymes. This means direct pharmacokinetic competition with propofol or midazolam at the metabolic level is not expected [5]. However, the peptide's adipose-tissue activity could theoretically alter the volume of distribution of highly lipophilic anesthetic agents like propofol over time in patients who have experienced significant fat loss, though this effect would be very modest and clinically likely imperceptible for most patients.

Neuromuscular Blocking Agents

Neuromuscular blocking drugs (NMBDs) such as rocuronium and succinylcholine act at the neuromuscular junction, a site entirely distinct from AOD-9604's adipose-tissue target. No receptor overlap or metabolic pathway competition has been identified in the preclinical or clinical literature for this peptide class. Based on available mechanistic data, NMBDs can be dosed per standard weight-based protocols without AOD-9604-specific adjustment [6].

Opioid Analgesics

Growth hormone axis peptides have historically raised interest around endogenous opioid interactions. Full-length GH can modulate beta-endorphin release, but AOD-9604 does not appear to activate the full GH receptor signaling cascade. A 2000 preclinical study in rodent models found no opioid receptor binding for the 176-191 fragment [7]. Opioid analgesic requirements should not be assumed to differ in AOD-9604 users, though the absence of human trial data means this remains a theoretical rather than confirmed safety point.

Perioperative Protocol: Practical Guidance for Patients and Clinicians

Pre-Surgical Disclosure

Every patient using AOD-9604 must disclose this to their anesthesiologist and surgeon during the pre-operative assessment. The peptide is not detectable on standard preoperative drug screens and is not automatically flagged by pharmacy interaction checkers. Patients should bring the product label or the prescribing clinician's documentation to their pre-operative appointment.

The American Society of Anesthesiologists (ASA) guidance on herbal and supplement use states: "Many herbal medications and supplements have pharmacological effects that may interact with anesthetic drugs or affect the patient's perioperative course, and patients should disclose all supplements to their anesthesia team" [8]. While AOD-9604 is a peptide rather than an herbal supplement, the same disclosure principle applies given the absence of an FDA-approved label.

Recommended Pause Duration

Based on AOD-9604's approximately 30-minute plasma half-life and the lack of evidence for receptor-level effects persisting beyond 48 hours post-dose, a 7-day pre-surgical pause is a reasonable conservative standard. This recommendation aligns with general expert consensus for off-label injectable peptides and mirrors the pause period recommended for most growth hormone secretagogues by the Endocrine Society's clinical practice guidelines for GH therapy management [9].

Patients should resume AOD-9604 only after surgical wounds are healing appropriately, infection risk is minimal, and nutritional intake has normalized. A 14-day post-surgical pause is a prudent minimum for procedures involving general anesthesia or significant physiological stress.

Intraoperative Glucose Monitoring

Although AOD-9604 does not raise IGF-1 or directly cause insulin resistance, patients who combine it with caloric restriction programs may present with lower baseline blood glucose. Anesthesiologists should follow standard ASA fasting guidelines (no solids for 8 hours, clear liquids up to 2 hours before induction) and monitor intraoperative glucose per their institutional protocol for any patient on metabolic-modifying compounds [10].

Can You Drink Alcohol While Taking AOD-9604?

No published pharmacokinetic study has examined the co-administration of alcohol and AOD-9604. This is a gap in the literature, not a cleared safety statement.

What the Mechanism Suggests

Alcohol is metabolized primarily by alcohol dehydrogenase and CYP2E1 in the liver. AOD-9604 is metabolized by peptidases in the blood and peripheral tissues. Parallel metabolic pathways mean direct pharmacokinetic competition is unlikely. At the pharmacodynamic level, alcohol suppresses lipolysis acutely by increasing hepatic NADH, which may blunt AOD-9604's intended fat-mobilizing effect during the period of alcohol metabolism [11].

Practical Guidance

Heavy or chronic alcohol use adds perioperative risk independent of any peptide interaction. Alcohol can impair wound healing, increase infection risk, and alter anesthetic requirements through tolerance mechanisms. The CDC defines heavy drinking as more than 14 drinks per week in men or more than 7 drinks per week in women, and surgical outcomes worsen at this threshold [12]. Patients combining AOD-9604 with alcohol should reduce or eliminate alcohol consumption in the 4 to 8 weeks before elective surgery regardless of any peptide-specific interaction.

General Drug Interactions: What Else to Watch For

Insulin and Oral Hypoglycemics

AOD-9604 does not raise blood glucose in human clinical trials [2]. Patients already taking insulin, metformin, or other glucose-lowering agents should not experience additive hypoglycemia from AOD-9604 alone. Combined use with GLP-1 receptor agonists such as semaglutide or tirzepatide is increasingly common in telehealth weight-management programs. In STEP-1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [13]. Adding AOD-9604 to this regimen is purely additive from a weight-loss goal standpoint, but the combination lacks any controlled safety or efficacy data. Patients pursuing both agents should be monitored for cumulative caloric restriction effects that may exaggerate hypoglycemia risk.

Thyroid Medications

Full-length growth hormone accelerates peripheral conversion of T4 to T3 and can reduce TSH. AOD-9604, because it does not activate the full GH receptor, is not expected to meaningfully affect thyroid axis function. A preclinical study in rodent adipocytes showed no upregulation of type 2 deiodinase (the enzyme converting T4 to T3 in adipose tissue) following AOD-9604 exposure [7]. Patients on levothyroxine do not need preemptive dose adjustments for AOD-9604 initiation, though annual thyroid function monitoring remains standard of care.

Corticosteroids

Corticosteroids antagonize GH-stimulated lipolysis. If a patient is on systemic corticosteroids (for example, prednisone for an autoimmune condition), the intended lipolytic effect of AOD-9604 may be attenuated. This is not a safety interaction but an efficacy consideration. From a surgical standpoint, patients requiring stress-dose steroids perioperatively should continue their steroid protocol per standard anesthesia practice without modification for AOD-9604 [9].

Anticoagulants

No coagulation effects attributable to AOD-9604 have been reported in clinical trial safety data [4]. Unlike some peptide compounds (for example, BPC-157, which has proposed platelet-modulatory effects in animal models), AOD-9604 does not appear to alter platelet aggregation or clotting factor activity. Patients on warfarin, direct oral anticoagulants (DOACs), or antiplatelet agents should manage those medications according to their cardiologist's or surgeon's bridging protocol, not according to any AOD-9604-specific precaution.

Special Populations: Considerations Beyond Standard Surgical Risk

Patients Undergoing Bariatric Surgery

Patients seeking bariatric surgery are often using multiple weight-loss adjuncts, including AOD-9604. Bariatric procedures significantly alter GI anatomy and absorption. Post-bariatric pharmacokinetics for subcutaneous peptides are not expected to change substantially because absorption occurs at the subcutaneous injection site rather than the GI tract. Providers should focus on optimizing pre-surgical body composition and nutritional status, pausing AOD-9604 7 days before surgery, and reassessing peptide utility after the metabolic benefits of the surgery itself are established at 3 to 6 months post-operatively.

Patients With Obesity and Sleep Apnea

Sleep apnea increases anesthetic risk by complicating airway management and increasing sensitivity to sedatives and opioids. AOD-9604's modest fat-loss effects over time could theoretically improve sleep apnea severity, but no trial has examined this endpoint. The ASA recommends pre-surgical CPAP optimization for patients with known sleep apnea regardless of concurrent weight-loss therapy [8].

Post-Surgical Wound Healing

Growth hormone supports tissue repair through IGF-1-mediated collagen synthesis. Because AOD-9604 does not substantially raise IGF-1, it does not confer the wound-healing support that some patients assume it does based on its GH-fragment origin. Do not rely on AOD-9604 as a substitute for adequate protein intake (1.2 to 1.6 g/kg/day is a standard surgical recovery target) and micronutrient sufficiency in the post-operative period [9].

What to Tell Your Anesthesiologist: A Pre-Op Checklist

Bring the following information to your pre-operative appointment:

• The exact product name (AOD-9604 or HGH fragment 176-191) and the dose in micrograms
• The injection frequency and most recent injection date
• Any other peptides, GLP-1 agonists, or supplements being used concurrently
• Your prescribing or supervising clinician's contact information
• A note confirming you have paused the peptide at least 7 days before the scheduled procedure date

Your anesthesiologist is legally and ethically required to incorporate this information into the pre-operative assessment. Withholding peptide use is not advisable: even compounds without known anesthesia interactions can affect hemodynamics or metabolic parameters in ways that become clinically relevant under general anesthesia.